Drug Profile
AT 101
Alternative Names: (-)-gossypol; AT-101; Bcl-2/xL inhibitor - 3SBio; R-(-)-gossypol acetic acidLatest Information Update: 29 Sep 2022
Price :
$50
*
At a glance
- Originator National Institutes of Health (USA)
- Developer 3SBio; Ascenta Therapeutics; Ascentage Pharma; Mayo Clinic; National Cancer Institute (USA)
- Class Antineoplastics; Sesquiterpenes; Small molecules
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic lymphocytic leukaemia; Non-small cell lung cancer
- Phase I/II Multiple myeloma
- No development reported Solid tumours
- Discontinued Glioblastoma; Non-Hodgkin's lymphoma; Oesophageal cancer; Prostate cancer; Small cell lung cancer
Most Recent Events
- 29 Sep 2022 No development reported - Phase-II for Chronic lymphocytic leukaemia in Australia (PO)
- 29 Sep 2022 No development reported - Phase-II for Chronic lymphocytic leukaemia in China (PO)
- 15 Sep 2020 Phase-II clinical trials in Chronic lymphocytic leukaemia in Australia (PO) (Ascentage Pharma pipeline, September 2020)